Why the study?
Do acid-suppressing therapies or misoprostol prevent gastroduodenal lesions in patients taking NSAIDs, and what is the role of H pylori and prior mucosal injury?
Do acid-suppressing therapies or misoprostol prevent gastroduodenal lesions in patients taking NSAIDs, and what is the role of H pylori and prior mucosal injury?
Relapse of gastroduodenal lesions in NSAID users is highly site- and type-specific and not adversely affected by H pylori status, suggesting local mucosal factors drive ulcer development.
No takes yet. Share an insight, caveat, or question.
Prior endoscopic lesions predict site-specific NSAID ulcer recurrence; confirms local mucosal factors predominate over H pylori and guides targeted prophylaxis.
Christopher J. Hawkey (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: